BioCentury
ARTICLE | Clinical News

ADI-PEG 20: Phase II data

November 4, 2013 8:00 AM UTC

The open-label, U.K. Phase II ADAM trial in 68 patients with MPM showed that once-weekly 36.8 mg/m 2 intramuscular ADI-PEG 20 plus best supportive care (BSC) for 6 months met the primary endpoint of improving median PFS vs. BSC alone (98 vs. 59 days, HR=0.53, 95% CI: 0.31, 0.9, p=0.02). In 39 ADI-PEG 20-treated patients evaluable for metabolic responses as measured by fluorodeoxyglucose PET (FDG-PET), there were 18 partial responses plus 12 cases of stable disease. ADI-PEG 20 was generally well tolerated. Data were presented at the World Conference on Lung Cancer in Sydney. ...